FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileLakewood-Amedex Biotherapeutics Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock Stock AnalysisComprehensive stock analysis for Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLABT
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
LABT
  1. Home
  2. Stocks
  3. Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc. Common Stock

🇺🇸LABT•NASDAQ

Lakewood-Amedex Biotherapeutics Inc. Common Stock

🇺🇸LABT•NASDAQ
Market cap
$428.74K

Your view on LABT

Mkt Cap
$428.74K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Lakewood-Amedex Biotherapeutics Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Kelvin Cooper
Headquarters
8031 Cooper Creek Blvd., Unit 103, University Park, FL, US
Industry
Biotechnology
Sector
Healthcare
CEO
Kelvin Cooper
Headquarters
8031 Cooper Creek Blvd., Unit 103, University Park, FL, US
Description

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C.

Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Lakewood-Amedex Biotherapeutics Inc. Common Stock. Starting points for Lakewood-Amedex Biotherapeutics Inc. Common Stock: EPS -$2.90, beta -4.76 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Lakewood-Amedex Biotherapeutics Inc. Common Stock. Trailing twelve-month EPS for Lakewood-Amedex Biotherapeutics Inc. Common Stock stands at -$2.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.49−$1.75−$0.59
Lowest estimate−$0.49−$1.75−$0.59
Highest estimate−$0.49−$1.75−$0.59
Number of analysts111
A year ago———
Growth vs a year ago———

Revenue estimates

TotalThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00
Number of analysts000
A year ago———
Growth vs a year ago———

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Lakewood-Amedex Biotherapeutics Inc. Common Stock. Lakewood-Amedex Biotherapeutics Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold LABT12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
DNLIDenali Therapeutics Inc.HealthcareNASDAQ$3.0B
DNTHDianthus Therapeutics, Inc.HealthcareNASDAQ$4.8B
DOSE.CNRapid Dose Therapeutics Corp.HealthcareCNQ$19.3M
DRMADermata Therapeutics, Inc.HealthcareNASDAQ$2.5M
DRMAWDermata Therapeutics, Inc.HealthcareNASDAQ$409
DRTSAlpha Tau Medical Ltd.HealthcareNASDAQ$1.1B
DRTSWAlpha Tau Medical Ltd.HealthcareNASDAQ$1.1B
DRUGBright Minds Biosciences Inc.HealthcareNASDAQ$201.2M
DRUG.CNBright Minds Biosciences Inc.HealthcareCNQ$973.0M
DSGNDesign Therapeutics, Inc.HealthcareNASDAQ$577.6M
DTC.CNDefence Therapeutics Inc.HealthcareCNQ$40.5M
DTCFFDefence Therapeutics Inc.HealthcareOTC$22.9M
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Lakewood-Amedex Biotherapeutics Inc. Common Stock executives and directors. Shares of Lakewood-Amedex Biotherapeutics Inc. Common Stock have traded between $1.66 and $98.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Lakewood-Amedex Biotherapeutics Inc. Common Stock. Coverage tracks Lakewood-Amedex Biotherapeutics Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Lakewood-Amedex Biotherapeutics Inc. Common Stock.

LABT AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1